BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

908 related articles for article (PubMed ID: 16481415)

  • 1. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study.
    Hernández D; Muriel A; Abraira V; Pérez G; Porrini E; Marrero D; Zamora J; González-Posada JM; Delgado P; Rufino M; Torres A
    Nephrol Dial Transplant; 2012 Jan; 27(1):417-22. PubMed ID: 21622985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients.
    Hillebrand U; Suwelack BM; Loley K; Lang D; Reuter S; Amler S; Pavenstädt H; Hausberg M; Büssemaker E
    Transpl Int; 2009 Nov; 22(11):1073-80. PubMed ID: 19624495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants and patterns of renin-angiotensin system inhibitors' prescription in the first year following kidney transplantation.
    Thilly N; Bayat S; Alla F; Kessler M; Briançon S; Frimat L
    Clin Transplant; 2008; 22(4):439-46. PubMed ID: 18318741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report.
    Opelz G; Zeier M; Laux G; Morath C; Döhler B
    J Am Soc Nephrol; 2006 Nov; 17(11):3257-62. PubMed ID: 17035607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?
    Courtney AE; McNamee PT; Nelson WE; Maxwell AP
    Nephrol Dial Transplant; 2006 Dec; 21(12):3550-4. PubMed ID: 16968729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of pre-operative electrocardiographic abnormalities and cardiovascular risk factors on patient and graft survival following renal transplantation.
    Woo YM; McLean D; Kavanagh D; Ward L; Aitken S; Miller GJ; Egan P; Hughes K; Clark L; Carswell K; Morris ST; Northridge DB; Rodger RS; Jardine AG
    J Nephrol; 2002; 15(4):380-6. PubMed ID: 12243367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis.
    Fang W; Oreopoulos DG; Bargman JM
    Nephrol Dial Transplant; 2008 Nov; 23(11):3704-10. PubMed ID: 18567695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use during postischemic acute transplant failure and renal allograft survival.
    Heinze G; Collins S; Benedict MA; Nguyen LL; Kramar R; Winkelmayer WC; Haas M; Kainz A; Oberbauer R
    Transplantation; 2006 Dec; 82(11):1441-8. PubMed ID: 17164715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy.
    Zaltzman JS; Nash M; Chiu R; Prasad R
    Nephrol Dial Transplant; 2004 Apr; 19(4):940-4. PubMed ID: 15031353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003.
    Lamb DA; Eurich DT; McAlister FA; Tsuyuki RT; Semchuk WM; Wilson TW; Blackburn DF
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):228-35. PubMed ID: 20031842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of survival after cardiac arrest in outpatient hemodialysis clinics.
    Pun PH; Lehrich RW; Smith SR; Middleton JP
    Clin J Am Soc Nephrol; 2007 May; 2(3):491-500. PubMed ID: 17699456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
    Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteinuria after conversion to sirolimus in kidney transplant recipients: impact of pre-existing proteinuria, graft function, and angiotensin-converting enzyme inhibitors/angiotensin-receptor antagonists.
    Marx C; Busch M; Ott U; Gerth J; Wolf G
    Clin Transplant; 2010; 24(5):626-30. PubMed ID: 19925471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers.
    Opelz G; Döhler B
    Transplantation; 2014 Feb; 97(3):310-5. PubMed ID: 24492421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.